Hanuveda

No, and we would be cautious with anyone who says there is. There is no classical Ayurvedic description of fatty liver — the term usually presented as its Sanskrit name is a modern coinage — so there is no long treatment tradition specific to it. The available studies are small, uncontrolled, and give diet and exercise to everyone, which makes it impossible to attribute results to the herb. Meanwhile, the safety data give real cause for caution.

Not automatically, and the data from India are sobering. A single-centre study found 2.3% of patients hospitalised with liver dysfunction had injury attributable to Ayurvedic and herbal medicines; among 27 studied in detail, 21 had liver fibrosis and six died. Chemical analysis found high arsenic and mercury levels significantly associated with death. Most were unlabelled polyherbal preparations. A separate large series found almost half of patients with Ayurvedic drug-induced liver injury died of progressive liver failure. This is why our protocol prescribes less, not more.

It is worth stopping and telling your doctor. Guduchi/Giloy (Tinospora cordifolia) has a published case series linking it to autoimmune-like hepatitis, and a US case series describes a patient developing acute liver injury after taking Giloy Kwath alone. There is an unresolved debate about whether species substitution explains some cases, but in a patient who already has liver disease, the safe course is not to take it.

It is the most commonly prescribed Ayurvedic liver formulation in India, and it contains Parada (mercury). Our view is that giving a mercury-containing preparation to someone with liver disease needs specific justification, particularly given that heavy metal content was significantly associated with death in the Indian case series. We offer plant-only protocols by default, and if you would rather avoid herbo-mineral products entirely, that is a clinically sound choice.

It is a fibrosis score calculated from your age and three numbers you probably already have — AST, ALT and platelet count. It costs nothing and it tells us roughly whether your liver has significant scarring. That distinction matters enormously: simple fat is largely reversible, advanced fibrosis is not, and patients with cirrhosis need six-monthly ultrasound surveillance for liver cancer. Ask your doctor to calculate it.

The thresholds are specific. Around 5% reduces liver fat. 7–10% improves inflammation. 10% or more is where fibrosis regression appears — 45% of patients in the biopsy study. So we set 10% as the target where it is achievable, at a rate of about half to one kilogram per week. Faster is not better; rapid loss can actually worsen the liver.

No. The name refers to how the condition originates, not to alcohol being harmless once you have it. Current classification includes a specific category (MetALD) for metabolic fatty liver combined with alcohol use, precisely because the two compound each other. Alcohol cessation is the single clearest instruction on this page, and it often produces enzyme improvement within weeks.

Ultrasound grading tells you roughly how much fat is present. It does not tell you whether there is inflammation or scarring, which is what actually determines your risk. A Grade 2 liver with no fibrosis is very different from a Grade 2 liver with F3 fibrosis. Get a FIB-4 score and, if indicated, elastography — those answer the question that matters.

Yes, and you should know about them. Resmetirom was approved in 2024 for MASH with fibrosis, and GLP-1 receptor agonists have shown MASH resolution in trials while producing substantially more weight loss than lifestyle programmes. If you have advanced disease or significant obesity, these are worth discussing with a hepatologist. We would rather tell you than have you find out later.